Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda in FAP-α Positive Solid Tumors September 16, 2026
First Patient dosed in Ph 1 Trial of CBX-663 for Treatment of Multiple Hematologic and Solid Malignancies September 16, 2026
US FDA IND Clearance and Australian Regulatory Clearance granted for [²²⁵Ac]Ac-FL-261 Ph 1 Clinical Trial September 16, 2026
FDA IND clearance to initiate a first-in-human Ph 1 trial of lead peptide-drug conjugate program TS-104 September 16, 2026
Styx Biotechnologies Announces Strategic Agreement with ZoeNCure Therapeutics to Accelerate Next-Gen ADC Pipeline to Clinic September 9, 2026
Treeline Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate TLN-121 with CD20xCD3 T-Cell-Engaging Bispecific Antibodies September 9, 2026
Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors September 9, 2026
China’s Simnova Bags USD59.5 Million in New Funding to Advance Off-the-Shelf Cell Therapies September 9, 2026
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors September 9, 2026
Positive Outcome Announced from First Planned Interim Efficacy Analysis from FORTE Basket Study of Plixorafenib Monotherapy in Advanced Solid Tumors with BRAF Fusions September 9, 2026
First patient dosed in Ph 1 trial of ABSK211 for advanced solid tumors with KRAS alterations September 2, 2026
Confirmed Durable Partial Response Achieved in Ph 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy September 2, 2026
IDMC recommends to continue patient enrolment in Ph 1 ZIMA-101 trial in solid tumor patients August 25, 2026
Akiram Therapeutics and ITM Sign Lutetium-177 Supply Agreement to Support Development of AKIR001 for the Treatment of Solid Tumors August 25, 2026
FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors August 25, 2026
FDA clears IND application to proceed to Ph 1/2 clinical trial for XTX501 in solid tumors August 20, 2026
Tikva Allocell Secures $8 Million Series A Financing to Advance Engineered Off-the-Shelf Cell Therapies for Solid Tumors July 28, 2026
Lupin spins out two oncology programs LNP7457 (PRMT5) and LNP8701 (SOS1) into Kaveri Therapeutics July 28, 2026
BeOne Medicines Expands U.S. Manufacturing with More Than $1 Billion Investment to Advance Cancer Medicines July 28, 2026
